Forbes July 5, 2023
Over a million patients worldwide get a new pacemaker every year. The vast majority of those pacemakers require surgery to be implanted and use electric wires that connect to the heart known as “leads.” The next generation of the technology, known as “leadless” pacemakers, don’t require surgery and are injected using a catheter into a vein, but so far have only worked in a single chamber of the heart. Today the FDA approved Abbott’s leadless pacemaker, the Aveir DR, for both chambers of the heart.
This was a substantial technical feat. Abbott’s proprietary system works by transmitting high frequency electric pulses that take advantage of the electric conductivity of blood to deliver the signal. In a clinical trial, over 97%...
Today's Sponsors
Today's Sponsor